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Abstract
A set of new pyrimido[5,4-b ]indole derivatives that are structurally related to some non-nucleoside HIV-1 reverse transcriptase
inhibitors were synthesized and biologically evaluated for their activity as inhibitors of wild and mutant HIV-1 RT types in an
‘in vitro’ recombinant HIV-1 RT screening assay, as well as anti-infectives in HLT4lacZ-1IIIB cells. Preliminary structure–activity
relationships suggest that activity is promoted by simultaneous substitution in positions 2 and 4, especially when chains of
alkyldiamine type are present, and by electron-releasing substituents (methoxy) in positions 7 and 8. The inactivity or the very low
activity of title derivatives does not suggest interest in AIDS therapy. © 1999 Elsevier Science S.A. All rights reserved.
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1. Introduction
Once the HIV virus has entered into the host cell,
the transcription process is set off, whereby, starting
from viral RNA, the proviral DNA is synthesized
which later will integrate into the genome of the cell.
This activity is carried out by the reverse transcriptase
enzyme, a characteristic enzyme of the retroviruses,
and due to its uniqueness it is considered to be a
fundamental target for the development of new anti-
retroviral agents.
With the discovery of non-nucleoside agents such as
HEPT [1] or TIBO [2] (Fig. 1), that are capable of
inhibiting this enzyme, a new field has been initiated
in anti-AIDS research, revealing a great variety of
compounds such as bis(heteroaril)piperazines (BHAPs)
[3], TSAO-T [4], or alkenyldiarylmethanes (ADAMs)
[5]. Delavirdine (U-90152s), a BHAP non-nucleoside
reverse transcriptase inhibitor, has recently been ap-
proved by the FDA (Fig. 1). Although these com-
pounds belong to very different structural groups,
their interaction with the enzyme in an allosteric site is
a common mechanism [6].
The good oral bioavailability that the non-nucleoside
inhibitors present and the lack of significant toxicities
to the active doses have constituted a stimulus for
scientific research in an attempt to find more potent
and selective compounds.
However, it has been determined that the more spe-
cific an antiviral compound in its antiviral action, the
faster it should be in the development of virus-drug
resistance. Taking into account that the compounds
described up to now are highly specific for the reverse
transcriptase, the rapid development of resistances can
be related to this specific character. Thus, through
directed studies of mutagenesis, in which the mutation
of a single aminoacid can be unequivocally associated
with the appearance of resistant viruses, the role which
the aminoacids of positions 100, 103, 106, 138, 181,
188 and 236 of the HIV-1 reverse transcriptase play in
the appearance of resistance to compounds TIBO,
HEPT, Nevirapine, Pyridinones, TSAO and BHAPs
was confirmed [7–9] (Fig. 1).* Corresponding author.
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Fig. 1.
Fig. 3.
reverse transcriptase inhibitors (wild and mutant types)
(Fig. 2).
In their structure, these compounds possess an in-
dolic ring, characteristic of compounds of high activity
as antiretrovirals (BHAPs, Fig. 1), fusioned with a
pyrimidine ring, present in non-nucleoside analogs
(TSAO-T, HEPT, Fig. 1) as well as in nucleoside
analogs such as ddl or ddC (Fig. 3), up to now the most
efficient, along with AZT, in the therapy of AIDS.
Taking as a reference these structures I and II,
different modifications have been carried out in order
to obtain data which permit the establishment of the
opportune structure–activity relationships in this type
of compound.
Derivatives I have substituents in position 2, while
derivatives II in positions 2 and 4. These substituents
have been selected using the structure–activity relation-
ships cited in the bibliography as reference for the
different groups of non-nucleoside compounds, espe-
cially in the case of the BHAPs [3,16] and the quinoline
derivatives (Fig. 1) [17].
Thus, by analogy to the quinoline series, aliphatic
amines and heterocyclic rings are selected as sub-
stituents. In the case of 2, these substituents are con-
nected directly to position 2 of the pyrimido-
[5,4-b ]indol-4-one ring. While maintaining these sub-
stituents in position 2, different primary alkyldiamines
are selected and introduced in position 4, series 4.
Bearing in mind the SAR data in the BHAP series,
secondary aliphatic cyclic amines (morpholine, pipe-
ridine, phenylpiperazines,...) are selected as substituents
in series 6, where they are connected to position 2 by a
methylene bridge. For series 8, alkyldiamines and sec-
ondary aliphatic cyclic amines are introduced simulta-
neously in position 4.
The increase in activity observed in the BHAP series
when electrodonor groups are introduced in the indole
ring lead us to introduce the methoxy substituent in
positions 7 and 8 of the pyrimido[5,4-b ]indole ring.
2. Chemistry
The synthesis of the compounds described in the
present work has been carried out according to Scheme
1. The starting products, ethyl 3-aminoindol-2-carboxy-
late (1a) and ethyl 3-amino-2-carboxylate-5,6-
Certain mutations are related to the use of specific
compounds; thus, the substitution of a proline in posi-
tion 236 by a leucine (mutant type P236L) offers resis-
tance to the BHAPs; other mutations, such as the
substitution of a tirosine in position 181 by a cysteine
(mutant type Y181C), appear after treatments with
TIBO, HEPT, Nevirapine, Pyridinones and BHAPs,
among others, observing, in addition, the existence of
crossed resistances among the majority of the nu-
cleoside inhibitors [10,11].
It was also observed that, within a determined type
of non-nucleoside inhibitor, small modifications in their
structures can increase and even restore the activity of
the new resulting compounds against the resistant HIV-
1 strains [12].
Taking into consideration all of the aforementioned,
and within the research carried out on new anti-AIDS
agents by our team [13–15], we present the synthesis
and preliminary study of new pyrimido[5,4-b ]indol-4-
one (I) and pyrimido[5,4-b ]indole (II) analogs as HIV-1
Fig. 2.
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Scheme 1. Reagents: (a) R2CN:HCl (gas); (b) POCl3; (c) NHR4R4% ;
(d) ClCH2CN; (e) NHR2R2%. R7, R8H; CH3O.
3. Biology
Initially, the enzyme inhibitory activity of each com-
pound was evaluated in an in vitro recombinant HIV-1
RT wild type screening assay [21–23], at a concentra-
tion of 5–50 mM. The compounds whose inhibitory
activities were lower than 50% at 50 mM were consid-
ered inactive. The active compounds were subsequently
evaluated as inhibitors of the mutant HIV-1 RT Y181C
enzyme type. Finally, these selected compounds were
assayed as anti-infectives in HLT4lacZ-1 cells, and their
potential toxicity was evaluated simultaneously [24,25].
The data corresponding to the active products are
shown in Table 3. The compounds that do not appear
in Table 3 were considered inactive.
4. Discussion
From the initial biological activity data obtained in
the in vitro inhibition assay of HIV-1 RT wild type, the
following observations can be proposed:
1. The presence of an oxo substituent in position 4 of
the pyrimido[5,4-b ]indole ring is unfavorable for
activity. All the analogs of series 2 and 6 studied
were inactive in this assay.
2. The presence of a methylene bridge connecting
amine substituents in position 2 provokes a notable
decrease in activity. The analogs of series 6 and 8
are also inactive.
3. The simultaneous substitution in positions 2 and 4 is
favorable for activity, especially when chains of
alkyldiamine type are present. In this way, the active
products are included in series 4 (Table 3).
4. The introduction of the methoxyl groups at posi-
tions 7 and 8 is beneficial; in general, an increase in
activity is observed.
In this way, compounds 4e (IC5037.0 mM), 4i
(IC5029.2 mM), 4j (IC5037.8 mM), 4m (IC5069.4
mM) and 4t (IC5034.1 mM) were selected; they are
now being studied as inhibitors of the mutant HIV-1
RT Y181C enzyme. The derivatives 4e, 4i and 4j show
an activity which is similar to that found against the
wild type; no significant differences were found among
the IC50 values for the mutant and wild types. In the
case of the derivatives 4m and 4t, a notable decrease in
activity against the mutant type is observed.
As an initial approximation, it could be said that the
presence of an electrodonor group in positions 7 and 8
and the presence of either a system which is rich in p
electrons (furane ring) or an electrodonor group
(dimethylamine) in position 2, is favorable for activity
against the mutant type. On the contrary, the absence
of methoxy substituents in the indole ring and the
presence of a heteroaromatic ring deficient in p elec-
trons (pyridine ring) in position 2 leads to compounds
dimethoxyindole (1b), were synthesized with high yield
using previously described methods [18,19]. The con-
densation of 1 with the appropriate nitriles, in a dry
dioxane medium and under a flow of HCl (g), gave the
corresponding 3,4-dihydro-5H-pyrimido[5,4-b ]indol-4-
ones (2, Table 1). The treatment of these compounds 2
with POCl3 and dry dioxane at reflux temperature leads
to 4-chloro-5H-pyrimido[5,4-b ]indoles (3, Table 2). By
reaction of these compounds with different primary or
secondary amines, in the presence of sodium carbonate
in refluxing ethanol or dioxane, compounds 4 were
synthesized (Table 2). Application of the method of
Shishoo et al. [20] for the obtainment of highly func-
tional pyrimidine rings in a single step allows us to
synthesize 2-chloromethyl-5H-3,4-dihydropyrimido[5,4-
b ]indol-4-one (5), by reaction of 1a with chloroacetoni-
trile, with dry dioxane under a flow of HCl (g). The
reaction of 5 with the appropriate secondary amines,
with ethanol as the solvent and with sodium carbonate,
leads to compounds 6 (Table 1). The oxygen in position
4 of compounds 6 can be substituted by chloro, as in
the preceding case, through reaction with POCl3, in
refluxing dry dioxane, thereby obtaining derivatives 7
(Table 2). The reaction of the last compounds with the
selected amines leads to the corresponding derivatives 8
(Table 2).
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Table 1
Physical constants of 3,4-dihydro-5H-pyrimido[5,4-b ]indol-4-one analogs (2, 5, and 6)
Formula cM.p. (°C) RecrystallizationComp. R2 Yield (%)
aR7 R8
solvent b
C14H9N3O2A422a 270–2732%-furyl H H
278–280 60 B C13H13N3O42b 2%-furyl CH3O CH3O
C12H12N4OC632c 290–293N(CH3)2 H H
B C14H16N4O32d N(CH3)2 CH3O CH3O 296–298 45
C15H10N4OB512e 295–2992%-pyridyl H H
\300 58 A C17H14N4O32f 2%-pyridyl CH3O CH3O
D C15H10N4O182g \3003%-pyridyl H H
\300 50 A C17H14N4O32h 3%-pyridyl CH3O CH3O
282 (dec.) 43 E C11H18ClN3O5 CH2Cl H H
196–197 42 A6a CH2N(C2H5)2 C15H18N4OH H
43 A6b methyl-N-morpholinyl H H 237–239 C15H16N4O2
A47 C16H18N4O6c 235 (dec.)methyl-N-piperidinyl H H
41 A6d methyl-N-[4-(2%-methoxyphenyl)]piperazinyl H H 226–227 C22H23N5O2
C23H25N5O2A656e 223–225methyl-N-[4-(2%-ethoxyphenyl)]piperazinyl H H
254–256 62 A C20H20N6O6f methyl-N-[4-(2%-pyridyl)]piperazinyl H H
C21H20ClN5OF326g 252–253methyl-N-[4-(4%-chlorophenyl)]piperazinyl H H
142–144 17 B6h methyl-N-[4-(2%-furoyl)]piperazinyl H C20H19N5O3H
20 A6i methyl-N-[4-(3%,4%-methylendioxophenyl)] C23H23N5O3H H 254–256
piperazinyl
a Value of the final transformation is expressed.
b Recrystallization solvent: A, 2-PrOH; B, EtOH:H2O; C, MeOH:H2O; D, toluene; E, 2-PrOH:dioxane; F, dioxane.
c All compounds were analyzed for C, H, N and results were in agreement to within 90.4% of the theoretical values.
that, although they possess activity against the wild
type, they lose it against the mutant type.
The interpretation of the results obtained in the
assay for determining the anti-infective activity of
these compounds is difficult, due to the high cytotoxi-
city that they show: unfortunately, the anti-infective
effective doses are found to be very near the cyto-
toxic doses. As the described compounds show low
potency against HIV-1 infected cells, no molecular
modeling studies have been performed, so we do not
know whether the butterfly-like model matches with
these compounds [26].
The biological data obtained confirm the interest
that these new derivatives could have in the field of
anti-AIDS therapy; however, due to the high cytotox-
icity shown by these derivatives, new structural mod-
ifications are now being proposed in this type of
nucleus. These modifications could permit the increase
of inhibitory activity on the HIV-1 RT mutant types,
decreasing the toxic effects until an adequate safety
margin is reached.
5. Experimental protocols
5.1. Chemistry
General laboratory chemicals were purchased from
Merck, Sigma, Janssen, and Scharlau.
All the new compounds were characterized by
elemental analysis, IR and 1H NMR. The IR spectra are
recorded on a Perkin–Elmer FT 681 using KBr pellets.
The 1H NMR spectra are obtained on a Bruker AC-200E
(200 MHz) instrument with Me4Si as the internal
standard, and at a concentration of approximately 0.1
g:ml. The mass spectra were obtained on a
Hewlett–Packard HP-5890 (GC:HPLC:DIP) instru-
ment. All spectra were consistent with assigned
structures. Thin layer chromatography was performed
on aluminum sheets precoated with silica gel (HF 254,
Merck). The developed chromatograms were viewed
under UV light or iodine revelation. Melting points were
determined on a Mettler FP82 hot stage apparatus
equipped with a FP800:FP80 processor and an Olympus
I.
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Table 2
Physical constants of 5H-pyrimido[5,4-b ]indole analogs (3, 4, 7 and 8)
R2 R4 R7 R8Comp. M.p. Formula
cYield Recrystallization
(%) a solvent b(°C)
2%-furyl Cl3a H H 217–220 51 A C14H8ClN3O
2%-furyl Cl CH3O CH3O 221–2233b 39 B C16H12ClN3O3
N(CH3)2 Cl H H3c 197–199 31 C C12H11ClN4·HCl
3d N(CH3)2 Cl CH3O CH3O 215–219 33 D C14H15ClN4O2·HCl d
3e 2%-pyridyl Cl H H 130–132 58 E C15H19ClN4
2%-pyridyl Cl CH3O CH3O3f 294–295 45 D C17H13ClN4O2·HCl
3g 3%-pyridyl Cl H H \300 (dec.) 16 D C15H9ClN4
3%-pyridyl Cl CH3O CH3O3h \300 28 F C17H13ClN4O2
4a 2%-furyl NH(CH2)2N(CH3)2 H H 220–225 14 E C18H19N5O
2%-furyl NH(CH2)3N(CH3)2 H H4b 92–95 6 E C19H21N5O
4c 2%-furyl NH(CH2)2N(C2H5)2 H H 187–189 18 E C20H23N5O
2%-furyl NH(CH2)2N(CH3)2 CH3O CH3O4e 235–239 10 E C20H23N5O3
2%-furyl NH(CH2)3N(CH3)2 CH3O CH3O4f 111–113 8 E C21H25N5O3
2%-furyl NH(CH2)2N(C2H5)2 CH3O CH3O4g 170–172 4 G C22H27N5O3
4h N(CH3)2 NH(CH2)2N(CH3)2 CH3O CH3O 205–206 (dec.) 6 G C18H26N6O2e
N(CH3)2 NH(CH2)3N(CH3)2 CH3O CH3O4i 148–151 12 G C19H28N6O2
4j N(CH3)2 NH(CH2)2N(C2H5)2 CH3O CH3O 141–144 19 G C20H30N6O2f
4k 2%-pyridyl N-morpholinyl H H \300 64 E C19H17N5O
2%-pyridyl N-[4-(2%-ethoxyphenyl)]piperazinyl H H4l 222–225 29 E C27H26N6O
4m 2%-pyridyl NH(CH2)2N(CH3)2 H H 242–245 22 E C19H19N6
2%-pyridyl NH(CH2)3N(CH3)2 H H4n 223–227 12 H C20H22N6
2%-pyridyl N(CH3)(CH2)2N(CH3)2 H H4o 116–117 23 E C20H22N6
2%-pyridyl NH(CH2)2N(C2H5)2 H H4p 207–209 8 I C21H24N6
2%-pyridyl NH(CH2)2N(CH3)2 CH3O CH3O4q 88–91 7 G C21H24N6O2
2%-pyridyl NH(CH2)3N(CH3)2 CH3O CH3O4r 133–135 6 G C22H26N6O2
4s 2%-pyridyl NH(CH2)2N(C2H5)2 CH3O CH3O 138–142 6 G C23H28N6O2
4t 3%-pyridyl NH(CH2)2N(CH3)2 H H 241–243 24 E C19H20N6
3%-pyridyl NH(CH2)3N(CH3)2 H H4u 192–195 7 G C20H22N6
4v 3%-pyridyl NH(CH2)2N(C2H5)2 H H 202–204 18 J C21H24N6
3%-pyridyl NH(CH2)2N(CH3)2 CH3O CH3O4w 162–166 7 G C21H24N6O2
3%-pyridyl NH(CH2)3N(CH3)2 CH3O CH3O4x 215–218 3 G C22H26N6O2
3%-pyridyl NH(CH2)2N(C2H5)2 CH3O CH3O4y 162–164 19 G C23H28H6O2
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8091 microscope provided with a video system and
were uncorrected.
Elemental analyses of vacuum-dried samples were
obtained on a Carlo Erba 1106 elemental analyzer (over
P2O5 at 1–2 mmHg, 24 h at 60–80°C). Results are
within 0.4% of theoretical values unless otherwise
indicated.
5.1.1. Ethyl 3-aminoindol-2-carboxylate (1a)
Previously reported [15].
5.1.2. Ethyl
3-amino-2-carboxylate-5,6-dimethoxyindole (1b)
Previously reported [14,15].
5.1.3. General procedure for the synthesis of
3,4-dihydropyrimido[5,4-b]indol-4-ones, 2-substituted
(2)
A flow of HCl (g) was passed through a mixture of 1
(50 mmol), the appropriate nitrile (120 mmol) and dry
dioxane (60 ml), with magnetic stirring and maintained
at 0°C for 9–12 h. The mixture was then set aside for
12 h at room temperature (r.t.). The mixture was
poured over ice (50 g) and then neutralized with 10%
NH4OH. The solid that precipitated was isolated by
filtration, dried and purified. In this way, compounds
2a, 2c, 2e and 2g were synthesized from 1a, and com-
pounds 2b, 2d, 2f and 2h were synthesized from 1b
(Table 1).
5.1.4. General procedure for the synthesis of
4-chloropyrimido[5,4-b]indoles, 2-substituted (3)
A mixture of 2 (24 mmol) and POCl3 (50 ml) was
refluxed with magnetic stirring for 8–10 h. The excess
reagent was eliminated by vacuum evaporation. 10%
NH4OH was added over the residue, until neutraliza-
tion was attained. The solid obtained was isolated by
filtration, washed with abundant H2O, dried and recrys-
tallized. If the compound is described as hydrochloride
(3c, 3d and 3f), this was obtained by dissolving the solid
isolated before recrystallization in AcOEt (100 ml). The
solution was dried over Na2SO4 and filtered. 35% HCl
(3 ml) was added over the solution with stirring and the
solid obtained was filtered, dried and recrystallized
(Table 2).
5.1.5. General procedure for the synthesis of
4-aminopyrimido[5,4-b]indoles, 2-substituted (4)
A mixture of 3 (4 mmol), the corresponding amine
(15 mmol), sodium carbonate (7 mmol) and the appro-
priate solvent (dioxane, 40–50 ml; ethanol, 40 ml) was
refluxed with constant stirring for 20–30 h. The mix-
ture was then poured over ice-cold water (200 ml). The
solid obtained was washed with abundant H2O, dried
and recrystallized. In this way, compounds 4a–c were
synthesized from 3a, compounds 4e–g from 3b, com-Ta
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Table 3
HIV-1 RT inhibitory activity of selected 5H-pyrimido[5,4-b ]indoles
% Inhibition IC50 (mM) bIC50 (mM) bComp. R2 % InhibitionR4 R7 R8
(wild type) a (Y181C type) a
35.974.097.537.04e 2%-furyl 83.196.0NH(CH2)2N(CH3)2 CH3O CH3O
78.595.9 29.2 78.595.9 32.24i N(CH3)2 NH(CH2)3N(CH3)2 CH3O CH3O
38.776.592.337.84j N(CH3)2 76.592.3NH(CH2)2N(C2H5)2 CH3O CH3O
66.496.8 c 69.4 28.492.44m –2%-pyridyl NH(CH2)2N(CH3)2 H H
–20.696.04t 65.496.43%-pyridyl 34.1NH(CH2)2N(CH3)2 H H
0.40 4.5U-90152s
a % inhibition at 50 mM (n3–5).
b Concentration–activity curves are carried out with four or more concentrations of test compounds; IC50 values are calculated from log curve.
c % inhibition at 100 mM (n3–5).
pounds 4h–j from 3d, compounds 4k–p from 3e, com-
pounds 4q–s from 3f, compounds 4t–v from 3g and
compounds 4w–y from 3h (Table 2).
5.1.6. 7,8-Dimethoxy-4-N-[2-(N,N-dimethylamino)]-
ethylamino-2-(2 %-furyl)pyrimido[5,4-b]indole (4e)
From 3b and 2-(N,N-dimethylamino)ethylamine. As
white powder. 1H NMR (DMSO-d6) d : 2.25 (s, 6H,
CH3N); 2.56 (t, 2H, CH2N); 3.75 (t, 2H, CH2N); 3.89
(s, 3H, CH3O); 3.90 (s, 3H, CH3O); 6.62 (d, 1H, H5%;
J2.4 Hz); 7.08–7.09 (m, 2H, H6, NH); 7.16 (s, 1H,
H4%); 7.50 (s, 1H, H9); 7.79 (s, 1H, H3%); 10.97 (s, 1H,
NH). MS-DIP (70 eV) m:e : 381 (M). Anal.
(C20H23N5O3) C, H, N.
5.1.7. 7,8-Dimethoxy-2-(N,N-dimethylamino)-4-N-
[3-(N,N-dimethylamino)]propylaminopyrimido[5,4-b]-
indole (4i)
From 3d and 2-(N,N-dimethylamino)propylamine. As
white powder. 1H NMR (DMSO-d6) d : 1.72–1.78 (m,
2H, CH2); 2.13 (s, 6H, CH3N); 2.30 (t, 2H, CH2N); 3.11
(s, 6H, CH3N); 3.50 (q, 2H, CH2N); 3.80 (s, 3H, CH3O);
3.83 (s, 3H, CH3O); 6.83 (s, 1H, NH); 7.02 (s, 1H, H6);
7.26 (s, 1H, H9); 10.05 (s, 1H, NH). MS-DIP (70 eV) m:e :
372 (M). Anal. (C19H28N6O2) C, H, N.
5.1.8. 4-N-[2-(N,N-Diethylamino)]ethylamino-7,8-
dimethoxy-2-(N,N-dimethylamino)pyrimido[5,4-b]indole
(4j)
From 3d and 2-(N,N-diethylamino)ethylamine. As
brown powder. 1H NMR (DMSO-d6) d : 1.04 (t, 6H,
CH3); 2.73–2.82 (m, 6H, CH2); 3.38–3.56 (m, 6H, CH2);
3.65 (q, 2H, CH2); 3.82 (s, 3H, CH3O); 3.85 (s, 3H,
CH3O); 7.01 (s, 1H, H6); 7.11 (s, 1H, NH); 7.29 (s, 1H,
H9); 10.35 (s, 1H, NH). MS-DIP (70 eV) m:e : 386 (M).
Anal. (C20H30N6O2) H, N; C: Calc. 62.15; Found:
61.74%.
5.1.9. 4-N-[2-(N,N-Dimethylamino)]ethyl-amino-2-
(2 %-pyridyl)pyrimido[5,4-b]indole (4m)
From 3e and 2-(N,N-dimethylamino)ethylamine. As
white needles. 1H NMR (DMSO-d6) d : 2.25 (s, 6H,
CH3N); 2.59 (t, 2H, CH2N); 3.80 (q, 2H, CH2N);
7.22–7.30 (m, 2H, H7, NH); 7.42 (t, 1H, H4%; J6.3 Hz);
7.52 (t, 1H, H8; J7.5 Hz); 7.67 (d, 1H, H6; J8.2 Hz);
7.92 (t, 1H, H5%; J7.7 Hz); 8.16 (d, 1H, H9; J7.8 Hz);
8.45 (d, 1H, H6%; J7.8 Hz); 8.72 (d, 1H, H3%; J4.4
Hz); 11.40 (s, 1H, NH). MS-DIP (70 eV) m:e : 274; 261;
78. Anal. (C19H20N6) C, H, N.
5.1.10. 4-N-[2-(N,N-Dimethylamino)]ethylamino-2-
(3 %-pyridyl)pyrimido[5,4-b]indole (4t)
From 3g and 2-(N,N-dimethylamino)ethylamine. As
yellow powder. 1H NMR (DMSO-d6) d : 2.29 (s, 6H,
CH3N); 2.63 (t, 2H, CH2N); 3.83 (q, 2H, CH2N);
7.24–7.32 (m, 2H, H7, NH); 7.50–7.56 (m, 2H, H8, H5%);
7.68 (d, 1H, H6; J8.1 Hz); 8.18 (d, 1H, H9; J7.7 Hz);
8.63 (d, 1H, H4%; J3.8 Hz); 8.77 (d, 1H, H6%; J7.8
Hz); 9.64 (s, 1H, H2%); 11.36 (s, 1H, NH). MS-DIP (70
eV) m:e : 332 (M). Anal. (C19H20N6) C, H, N.
5.1.11. 2-Chloromethyl-3,4-dihydropyrimido[5,4-b]-
indole (5)
A flow of HCl (g) was passed through a mixture of 1a
(13.25 g, 16 mmol), chloroacetonitrile (13.20 g, 42 mmol)
and dry dioxane (200 ml), maintained with vigorous and
constant stirring for 8 h. Next, the mixture was poured
over ice (100 g) and basified with 10% NH4OH. The
precipitate obtained was filtered, washed with abundant
H2O, dried and purified as white powder (Table 1).
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5.1.12. General procedure for the synthesis of 2-
(amino)methyl-3,4-dihydropyrimido[5,4-b]indol-4-ones
(6)
A mixture of 5 (2.5 g, 11 mmol), the appropriate amine
(25 mmol), sodium carbonate (15 mmol) and EtOH (60
ml) was refluxed with magnetic stirring for 3–8 h. The
mixture was poured over cold H2O (200 ml). When a
solid appeared, it was filtered, washed with abundant
H2O, dried and purified. When an oily residue appeared,
it was extracted with ethyl acetate (325 ml). The
organic extracts were dried with Na2SO4 and the solvent
was eliminated under reduced pressure. The solid ob-
tained was dried and recrystallized. In this way com-
pounds 6a–i were obtained (Table 1).
5.1.13. General procedure for the synthesis of
2-(amino)methyl-4-chloropyrimido[5,4-b]indole (7)
A mixture of 6 (6.6 mmol), POCl3 (15 ml) and dry
dioxane (20 ml) was refluxed with stirring for 18 h. The
solvent and excess reagent were eliminated under re-
duced pressure. Dioxane (10 ml) was poured over the
residue and the mixture was stirred. The solid obtained
was filtered, dried and purified. If the compound is
described as hydrochloride, this was obtained by dissolv-
ing the solid isolated in AcOEt (50 ml). The solution was
dried over Na2SO4 and filtered. 35% HCl (2 ml) was
added over the solution with stirring and the solid
obtained was filtered, dried and recrystallized. In this
way compound 7a (hydrochloride) was synthesized from
6b, compound 7b from 6d and compound 7c from 6e
(Table 2).
5.1.14. General procedure for the
4-amino-2-(amino)methylpyrimido[5,4-b]indoles (8)
A mixture of 7 (3.3 mmol), the appropriate amine (15
mmol), sodium carbonate (6.67 mmol) and dioxane (40
ml) was refluxed with stirring for 20–30 h. The mixture
was poured over ice-cold H2O (200 ml). The solid
obtained was filtered, washed with abundant H2O, dried
and recrystallized. In this way, compounds 8a–f were
synthesized from 7a and compounds 8g–i were synthe-
sized from 7c (Table 2).
5.2. Pharmacology
Poly-rA, oligo(dT)10 and deoxythymidine triphos-
phate (dTTP) were obtained from Pharmacia LKB
Biotechnology Inc. [35S]-dTTPa was purchased from
Amersham and DL-dithiothreitol was purchased from
Sigma. Nonidet P-40 was obtained from Boehringer–
Mannheim. The scintillation mixture used was Bio-
green-11 which was obtained from Scharlau. Glass
microfiber filters (Filtermats) were purchased from Ska-
tron Instruments.
U-90152s was kindly provided by the Upjohn Com-
pany, Kalamazoo, USA. Recombinant HIV-1 reverse
transcriptase (p66), wild and mutant types, purified
according to previously reported methods [17–19], were
also kindly provided by the Upjohn Company. Molt
3:HIV-1IIIB infected cells were kindly provided by Pro-
fessor F. Barin and Dr B. Janvier from Universite´
Franc¸ois Rabelais, Tours France; HLT4lacZ-1 cells
were kindly provided by Dr S. Saragosti from Hoˆpital
Cochin, Paris, France.
5.2.1. Re6erse transcriptase assay
Enzyme activity was measured in a total volume of
50 ml using a standard reaction mixture containing 50
mM Tris–HCl (pH 8.3), 20 mM DL-dithiothreitol, 60
mM NaCl, 0.05% Nonidet P-40, 10 mM MgCl2, 10
mg:ml poly-rA, 5 mg:ml oligo(dt)10 and 10 mM [35S]-
dTTPa (0.2 Ci:mmol). The mixture was pre-incubated
at 37°C for 2 min and the reaction was initiated by
adding the enzyme. Reaction was stopped after 10 min
with 50 ml of ice-cold 10% trichloroacetic acid. The
insoluble material was collected on glass microfiber
filters with a Skatron cell harvester and extensively
washed with 5% trichloroacetic acid. Filters were dried
in a microwave oven for 2 min, transferred to scintilla-
tion vials with 3 ml of cocktail and counted in a liquid
scintillation counter. All compounds tested were solubi-
lized in pure DMSO, diluted in water and assayed,
maintaining the final concentration of DMSO at 0.5%
(v:v).
5.2.2. Cell cultures
HIV-1IIIB chronically infected Molt-3 cells (Molt-3:
HIV-1IIIB) were cultured at 37°C with 5% CO2 in RPMI
1640 (Gibco) supplemented with 20% FCS (foetal calf
serum, Flow), 1% penicillin:streptomycin (Gibco), and
1% anti-PPLO (Gibco).
HT4lacZ-1 cells were cultured in DMEM (Dulbec-
co’s modification of Eagle medium, ICN Flow) supple-
mented with 2 mM L-glutamine (Gibco), 10% FCS
(Flow) and 1% penicillin:streptomycin (Gibco).
Titration of the virus was carried out by means of
syncytium formation assay, co-cultivating serial dilu-
tions from viral stocks with uninfected HLT4lacZ-1.
The concentration of the virus which caused 100–150
syncytia per well was used for the infection inhibition
assays.
5.2.3. Syncytia formation assay
The characteristics and use of HLT4lacZ-1 cells have
been described previously [20]. We have adapted their
use to perform a quantitative syncytia assay in 96-well
plates in order to quantify the inhibitory activity of the
synthesized products.
Briefly, 10 000 cells (200 ml):well were plated the day
before the assay. On the following day, the medium was
removed and 100 ml of product solution and 100 ml of
diluted virus were added. Controls with no product
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were also made. On the third day of post-infection, the
medium was removed and the cells were fixed for 5 min
at r.t. with 200 ml of a PBS solution containing 1%
formaldehyde (Merck) and 0.2% glutaraldehyde
(Merck). After two washes with 0.9% NaCl (Merck),
the cells were incubated for 1 h at 37°C with 200 ml of
a reaction mixture containing X-gal (5-bromo-4-chloro-
3-indolyl-b-D-galactopyranoside, Boehringer–Mann-
heim) (400 mg:ml), 4 mM potassium ferrocyanide
(Merck), and 2 nM MgCl2 (Merck) in PBS. After two
washes, 100 ml of 0.9% NaCl were added per well. The
plates were examined under the microscope and only
syncytia with three or more blue nuclei were counted in
the entire well.
5.2.4. Cell toxicity
Viability of HLT4lacZ-1 cells was evaluated in the
presence of the synthesized products using a modified
cell lytic assay described previously [21]. It was per-
formed in parallel with the syncytia formation assay.
A total of 200 ml of medium containing different
concentrations of the products or medium (control
wells) were added to 10 000 HLT4lacZ-1 cells plated the
day before. On the third day, the wells were washed
three times with PBs, and cell lysis was detected by
staining the plate for 10 min at r.t., with 20 ml:well of a
methanol:water (1:4 v:v) solution containing 0.5% crys-
tal violet (Merck). Controls of wells have been prepared
by staining the plates without cells (blank wells). Three
washes were carried out by immersion of the plates in
PBS, changing the PBS of the container each time. The
plates were wiped and 100 ml:well of 0.1% SDS (sodium
dodecyl sulfate, Sigma) were added. After complete
desegregation of the cell membranes, the O.D. at 540
nm was read in a Titertek Multiskan II autoreader
(Flow) and the percentage of viability (% V) was
calculated.
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